Vinorelbine tartrate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 100930

CAS#: 125317-39-7 (tartrate)

Description: Vinorelbine is a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic activity. Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity. This agent is also a radiation-sensitizing agent.


Chemical Structure

img
Vinorelbine tartrate
CAS# 125317-39-7 (tartrate)

Theoretical Analysis

MedKoo Cat#: 100930
Name: Vinorelbine tartrate
CAS#: 125317-39-7 (tartrate)
Chemical Formula: C53H66N4O20
Exact Mass: 1,078.43
Molecular Weight: 1,079.100
Elemental Analysis: C, 58.99; H, 6.16; N, 5.19; O, 29.65

Price and Availability

Size Price Availability Quantity
10mg USD 90 Ready to ship
25mg USD 180 Ready to ship
50mg USD 285 Ready to ship
100mg USD 450 Ready to ship
200mg USD 750 Ready to ship
500mg USD 1650 Ready to ship
Bulk inquiry

Related CAS #: 125317-39-7 (tartrate)   105661-07-2 (tartrate 1:1)   71486-22-1 (free base)  

Synonym: KW2307, KW-2307, KW 2307, vinorelbine tartrate, Navelbine, Biovelbin, Eunades

IUPAC/Chemical Name: methyl (3aR,3a1R,4R,5S,5aR,10bR)-4-acetoxy-3a-ethyl-9-((6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl)-5-hydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazole-5-carboxylate bis((2R,3R)-2,3-dihydroxysuccinate)

InChi Key: CILBMBUYJCWATM-PYGJLNRPSA-N

InChi Code: InChI=1S/C45H54N4O8.2C4H6O6/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7;2*5-1(3(7)8)2(6)4(9)10/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3;2*1-2,5-6H,(H,7,8)(H,9,10)/t28-,37-,38+,39+,42+,43+,44-,45-;2*1-,2-/m011/s1

SMILES Code: O=C(OC)[C@@]1([C@@]2(N(C3=C([C@@]24CCN5CC=C[C@@](CC)([C@H]1OC(C)=O)[C@@]45[H])C=C(C(OC)=C3)[C@]6(C[C@]7([H])C=C(CN(CC8=C6NC9=C8C=CC=C9)C7)CC)C(OC)=O)C)[H])O.O=C([C@@H]([C@H](C(O)=O)O)O)O.O=C([C@@H]([C@H](C(O)=O)O)O)O

Appearance: White to off-white solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:  

Biological target: Vinorelbine (ditartrate) inhibits the proliferation of Hela cells with IC50 of 1.25 nM.
In vitro activity: To determine the mechanism of protection from the pro-apoptotic action of metronomic vinorelbine the balance of the anti-apoptotic Bcl-2 and pro-apoptotic protein Bax (Fig. 6A) was investigated. Bcl-2 and Bax are players of the intrinsic mitochondrial apoptotic pathway and a low Bcl-2/Bax ratio leads to apoptotic cell death through mitochondrial outer membrane permeabilization (MOMP). Moreover, Bcl-2 downregulation has previously been implicated in the cell death caused by vinorelbine. Ten nanomolar vinorelbine downregulated the anti-apoptotic protein Bcl-2 in normoxia by 32% (P<0.01) at 24 h. Severe hypoxia also decreased Bcl-2 protein by 46% (P<0.001) but 10 nM vinorelbine did not further reduce Bcl-2 under these conditions (Fig. 6B). Similar changes were seen in the Bcl-2/Bax ratio (Fig. 6C). In particular, 10 nM vinorelbine decreased the Bcl-2/Bax ratio by 30% (P<0.05) in normoxia at 24 h, which is consistent with induction of apoptosis. Severe hypoxia decreased the Bcl-2/Bax ratio by 42% (P<0.01) while 10 nM vinorelbine did not have an additional effect. Reference: Int J Oncol. 2015 Aug; 47(2): 455–464. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501653/
In vivo activity: This study used a model previously described where JEG3 cells are xenografted subcutaneously into immune deficient (SCID) female mice and placental tumors allowed to form. Mice were then treated intravenously (via tail vein) with 1.25, 2.5 or 5 mg/kg vinorelbine, or vehicle control on days 6, 9 and 12 after xenograft inoculation. Compared to vehicle controls, vinorelbine at all doses significantly reduced xenograft volume 4 days after treatment (10 days after JEG3 inoculation) and each measured time point thereafter (12 and 14 days after inoculation) (Fig. 2A, B). Furthermore, vinorelbine treatment caused a significant, dose dependent reduction in xenograft tumor weight (harvested at the time of euthanasia) (Fig. 2C). There was a concordant dose dependent reduction in serum hCG from blood taken at the time of euthanasia. Significantly, at the top dose of vinorelbine (5 mg/kg) 6 out of 8 mice had a resolution of the tumor to the extent that no tumor could be found (Fig. 2C). Of these 6 mice, 5 had serum hCG levels below the detectable range of the assay (Fig. 2D). This suggests the possible complete absence of placental xenograft tumors in 5 mice. Reference: EBioMedicine. 2018 Mar; 29: 166–176. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925452/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 100.0 92.67
Ethanol 100.0 92.67
Water 100.0 92.67

Preparing Stock Solutions

The following data is based on the product molecular weight 1,079.10 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Mavroeidis L, Sheldon H, Briasoulis E, Marselos M, Pappas P, Harris AL. Metronomic vinorelbine: Anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition. Int J Oncol. 2015 Aug;47(2):455-64. doi: 10.3892/ijo.2015.3059. Epub 2015 Jun 19. PMID: 26095084; PMCID: PMC4501653. 2. Thomas-Schoemann A, Lemare F, Mongaret C, Bermudez E, Chéreau C, Nicco C, Dauphin A, Weill B, Goldwasser F, Batteux F, Alexandre J. Bystander effect of vinorelbine alters antitumor immune response. Int J Cancer. 2011 Sep 15;129(6):1511-8. doi: 10.1002/ijc.25813. Epub 2011 Apr 1. PMID: 21128224. 3. Hastie R, Lim E, Sluka P, Campbell L, Horne AW, Ellett L, Hannan NJ, Brownfoot F, Kaitu'u-Lino TJ, Tong S. Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy. EBioMedicine. 2018 Mar;29:166-176. doi: 10.1016/j.ebiom.2018.01.041. Epub 2018 Feb 2. PMID: 29429891; PMCID: PMC5925452. 4. Cui R, Yoshioka M, Takahashi F, Ishida H, Iwakami S, Takahashi K. Vinorelbine is effective for the malignant pleural effusion associated with lung cancer in mice. Anticancer Res. 2008 May-Jun;28(3A):1633-9. PMID: 18630520.
In vitro protocol: 1. Mavroeidis L, Sheldon H, Briasoulis E, Marselos M, Pappas P, Harris AL. Metronomic vinorelbine: Anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition. Int J Oncol. 2015 Aug;47(2):455-64. doi: 10.3892/ijo.2015.3059. Epub 2015 Jun 19. PMID: 26095084; PMCID: PMC4501653. 2. Thomas-Schoemann A, Lemare F, Mongaret C, Bermudez E, Chéreau C, Nicco C, Dauphin A, Weill B, Goldwasser F, Batteux F, Alexandre J. Bystander effect of vinorelbine alters antitumor immune response. Int J Cancer. 2011 Sep 15;129(6):1511-8. doi: 10.1002/ijc.25813. Epub 2011 Apr 1. PMID: 21128224.
In vivo protocol: 1. Hastie R, Lim E, Sluka P, Campbell L, Horne AW, Ellett L, Hannan NJ, Brownfoot F, Kaitu'u-Lino TJ, Tong S. Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy. EBioMedicine. 2018 Mar;29:166-176. doi: 10.1016/j.ebiom.2018.01.041. Epub 2018 Feb 2. PMID: 29429891; PMCID: PMC5925452. 2. Cui R, Yoshioka M, Takahashi F, Ishida H, Iwakami S, Takahashi K. Vinorelbine is effective for the malignant pleural effusion associated with lung cancer in mice. Anticancer Res. 2008 May-Jun;28(3A):1633-9. PMID: 18630520.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

 1: Chisholm JC, Merks JHM, Casanova M, Bisogno G, Orbach D, Gentet JC, Thomassin-Defachelles AS, Chastagner P, Lowis S, Ronghe M, McHugh K, van Rijn RR, Hilton M, Bachir J, Fürst-Recktenwald S, Geoerger B, Oberlin O; European paediatric Soft tissue sarcoma Study Group (EpSSG) and the European Innovative Therapies for Children with Cancer (ITCC) Consortium. Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). Eur J Cancer. 2017 Jul 21;83:177-184. doi: 10.1016/j.ejca.2017.06.015. [Epub ahead of print] PubMed PMID: 28738258.

2: Kolek V, Grygárková I, Koubková L, Skřičková J, Švecová J, Sixtová D, Bartoš J, Tichopád A. Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world set-up. PLoS One. 2017 Jul 21;12(7):e0181803. doi: 10.1371/journal.pone.0181803. eCollection 2017. PubMed PMID: 28732018.

3: Vanderpuye VDNK, Olopade OI, Huo D. Pilot Survey of Breast Cancer Management in Sub-Saharan Africa. J Glob Oncol. 2016 Dec 21;3(3):194-200. doi: 10.1200/JGO.2016.004945. eCollection 2017 Jun. PubMed PMID: 28717760; PubMed Central PMCID: PMC5493219.

4: Sathyamoorthy N, Magharla DD, Vankayalu SD. Effect of Surface Modification on the In vitro Protein Adsorption and Cell Cytotoxicity of Vinorelbine Nanoparticles. J Pharm Bioallied Sci. 2017 Apr-Jun;9(2):135-143. doi: 10.4103/jpbs.JPBS_258_16. PubMed PMID: 28717337; PubMed Central PMCID: PMC5508415.

5: Mamesaya N, Nakashima K, Naito T, Nakajima T, Endo M, Takahashi T. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature. BMC Cancer. 2017 Jul 6;17(1):471. doi: 10.1186/s12885-017-3468-1. PubMed PMID: 28683775; PubMed Central PMCID: PMC5501098.

6: Bilir C, Durak S, Kızılkaya B, Hacıbekiroglu I, Nayır E, Engin H. Efficacy of metronomic vinorelbine in elderly patients with advanced non-small-cell lung cancer and poor performance status. Curr Oncol. 2017 Jun;24(3):e199-e204. doi: 10.3747/co.24.3486. Epub 2017 Jun 27. PubMed PMID: 28680287; PubMed Central PMCID: PMC5486392.

7: Yamamoto N, Kenmotsu H, Yamanaka T, Nakamura S, Tsuboi M. Randomized Phase III Study of Cisplatin With Pemetrexed and Cisplatin With Vinorelbine for Completely Resected Nonsquamous Non-Small-Cell Lung Cancer: The JIPANG Study Protocol. Clin Lung Cancer. 2017 Jun 8. pii: S1525-7304(17)30169-9. doi: 10.1016/j.cllc.2017.05.020. [Epub ahead of print] PubMed PMID: 28668204.

8: Steger GG, Dominguez A, Dobrovolskaya N, Giotta F, Tubiana-Mathieu N, Pecherstorfer M, Ardizzoia A, Blasinska-Morawiec M, Espinosa E, Villanova G. Single-Agent Oral Vinorelbine as First-Line Chemotherapy for Endocrine-Pretreated Breast Cancer With Bone Metastases and No Visceral Involvement: NORBREAST-228 Phase II Study. Clin Breast Cancer. 2017 Jun 27. pii: S1526-8209(16)30562-6. doi: 10.1016/j.clbc.2017.05.012. [Epub ahead of print] PubMed PMID: 28666812.

9: Cortés J, Rugo HS, Awada A, Twelves C, Perez EA, Im SA, Gómez-Pardo P, Schwartzberg LS, Diéras V, Yardley DA, Potter DA, Mailliez A, Moreno-Aspitia A, Ahn JS, Zhao C, Hoch U, Tagliaferri M, Hannah AL, O'Shaughnessy J. Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Res Treat. 2017 Jun 13. doi: 10.1007/s10549-017-4304-7. [Epub ahead of print] PubMed PMID: 28612225.

10: Yamamura J, Masuda N, Yamamoto D, Tsuyuki S, Yamaguchi M, Tanaka S, Tsurutani J, Tokunaga S, Yoshidome K, Mizutani M, Aono T, Ooe A, Tanino H, Matsunami N, Yasojima H, Nakayama T, Nishida Y. Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015. Chemotherapy. 2017 Jun 13;62(5):307-313. doi: 10.1159/000475879. [Epub ahead of print] PubMed PMID: 28605730.

11: Guohua H, Hongyang L, Zhiming J, Danhua Z, Haifang W. Study of small-cell lung cancer cell-based sensor and its applications in chemotherapy effects rapid evaluation for anticancer drugs. Biosens Bioelectron. 2017 Nov 15;97:184-195. doi: 10.1016/j.bios.2017.05.050. Epub 2017 May 31. PubMed PMID: 28599178.

12: Passardi A, Fanini F, Turci L, Foca F, Rosetti P, Ruscelli S, Casadei Gardini A, Valgiusti M, Dazzi C, Marangolo M. Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results. Oncologist. 2017 Jun 7. pii: theoncologist.2017-0206. doi: 10.1634/theoncologist.2017-0206. [Epub ahead of print] PubMed PMID: 28592624.

13: Andersson M, López-Vega JM, Petit T, Zamagni C, Easton V, Kamber J, Restuccia E, Perez EA. Efficacy and Safety of Pertuzumab and Trastuzumab Administered in a Single Infusion Bag, Followed by Vinorelbine: VELVET Cohort 2 Final Results. Oncologist. 2017 Jun 7. pii: theoncologist.2017-0079. doi: 10.1634/theoncologist.2017-0079. [Epub ahead of print] PubMed PMID: 28592618.

14: Weiss GJ, Waypa J, Blaydorn L, Coats J, McGahey K, Sangal A, Niu J, Lynch CA, Farley JH, Khemka V. A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). Br J Cancer. 2017 Jun 27;117(1):33-40. doi: 10.1038/bjc.2017.145. Epub 2017 Jun 6. PubMed PMID: 28588322; PubMed Central PMCID: PMC5520208.

15: Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017 Jun 4. doi: 10.1056/NEJMoa1706450. [Epub ahead of print] PubMed PMID: 28578601.

16: Suda K, Rozeboom L, Rivard CJ, Yu H, Ellison K, Melnick MAC, Hinz TK, Chan D, Heasley LE, Politi K, Mitsudomi T, Hirsch FR. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer. 2017 Jul;109:1-8. doi: 10.1016/j.lungcan.2017.04.010. Epub 2017 Apr 19. PubMed PMID: 28577937.

17: Derks JL, van Suylen RJ, Thunnissen E, den Bakker MA, Groen HJ, Smit EF, Damhuis RA, van den Broek EC, Speel EM, Dingemans AC; PALGA group. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter? Eur Respir J. 2017 Jun 1;49(6). pii: 1601838. doi: 10.1183/13993003.01838-2016. Print 2017 Jun. PubMed PMID: 28572122.

18: Gadgeel SM. Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book. 2017;37:630-639. doi: 10.14694/EDBK_175188. PubMed PMID: 28561669.

19: Mencoboni M, Filiberti RA, Taveggia P, Del Corso L, Del Conte A, Covesnon MG, Puccetti C, Donati S, Auriati L, Amoroso D, Camerini A. Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC. Anticancer Res. 2017 Jun;37(6):3189-3194. PubMed PMID: 28551663.

20: Montagna E, Vingiani A, Maisonneuve P, Cancello G, Contaldo F, Pruneri G, Colleoni M. Unfavorable prognostic role of tumor-infiltrating lymphocytes in hormone-receptor positive, HER2 negative metastatic breast cancer treated with metronomic chemotherapy. Breast. 2017 Aug;34:83-88. doi: 10.1016/j.breast.2017.05.009. Epub 2017 May 23. PubMed PMID: 28544923.